Back to top
more

Ignyta, Inc. (RXDX)

(Real Time Quote from BATS)

$26.95 USD

26.95
NA

+0.03 (0.09%)

Updated Feb 8, 2018 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Merck (MRK) Stock Has Outperformed Industry YTD

by Zacks Equity Research

Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.

Prometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Prometheus Biosciences, Inc. (RXDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Neena Mishra headshot

Biotech ETFs Pop on M&A Resurgence

by Neena Mishra

2023 could be a year of heightened biotech dealmaking activity

Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 6.52% and 74.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -29.58% and 2.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Merck (MRK) Beats on Q1 Earnings and Sales, Ups 2023 View

by Zacks Equity Research

Merck (MRK) beats Q1 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.

AbbVie (ABBV) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

AbbVie (ABBV) delivered earnings and revenue surprises of 0.82% and 1.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Beats on Q1 Earnings, MRK to Buy RXDX & Other Updates

by Kinjel Shah

J&J (JNJ) beats earnings and sales estimates for the first quarter. Merck (MRK) offers to buy Prometheus Biosciences (RXDX).

Company News for Apr 18, 2023

by Zacks Equity Research

Companies in The News Are: MTB,RXDX,NFLX,ANET,MRK

Prometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?

by Zacks Equity Research

Prometheus Biosciences, Inc. (RXDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Prometheus (RXDX) Stock Surges 70% on Buyout Offer From Merck

by Zacks Equity Research

Prometheus (RXDX) is set to be acquired by Merck for $11 billion, adding Prometheus' lead product candidate, PRA023, to Merck's portfolio. Prometheus' stock is up 70%.

Prometheus Biosciences, Inc. (RXDX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 1.10% and 6.71%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Denali Therapeutics Inc. (DNLI) Surges 5.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Wall Street Analysts Think Prometheus Biosciences, Inc. (RXDX) Could Surge 33.49%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Prometheus Biosciences, Inc. (RXDX) points to a 33.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Ideas feature highlights: XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB

by Zacks Equity Research

XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB are part of the Zacks Investment Ideas article.

Andrew Rocco headshot

Biotech's Blockbuster Week: 3 Stocks to Watch

by Andrew Rocco

In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.

Wall Street Analysts Believe Prometheus Biosciences, Inc. (RXDX) Could Rally 26.51%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 26.5% in Prometheus Biosciences, Inc. (RXDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Prometheus Biosciences, Inc. (RXDX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -1.12% and 26.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

What Makes Prometheus Biosciences, Inc. (RXDX) a New Buy Stock

by Zacks Equity Research

Prometheus Biosciences, Inc. (RXDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Prometheus Biosciences, Inc. (RXDX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 6.52% and 81.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -12.25% and 91.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

VBI Vaccines, Inc. (VBIV) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -157.14% and 50.78%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Vertex (VRTX) delivered earnings and revenue surprises of 3.45% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 8.14% and 38.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -5.13% and 459.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?